A large randomized trial has demonstrated the utility of the mepolizumab (an anti-IL-5 recombinant humanized monoclonal antibody) for severe and refractory EGPA, and as corticosteroid-sparing agent [27]. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.